Sugi Predict

Sugi Predict / Targets / CDKL2

CDKL2

Cyclin-dependent kinase-like 2 · Q92772 · CDKL2 on Sugi Atlas →

2,511 patent compounds predicted against CDKL2, 2,044 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12293068 SCHEMBL12293068 0.61 2/20
SCHEMBL12292789 SCHEMBL12292789 0.51 2/20
SCHEMBL3383320 SCHEMBL3383320 0.47 2/20
Tandutinib Tandutinib (SCHEMBL927974) 1.00 1/20
SCHEMBL16793996 SCHEMBL16793996 1.00 1/20
Tandutinib Tandutinib (SCHEMBL2478362) 0.98 1/20
SCHEMBL13330466 SCHEMBL13330466 0.98 1/20
Tandutinib Tandutinib (SCHEMBL2496722) 0.93 1/20
SCHEMBL13330462 SCHEMBL13330462 0.93 1/20
SCHEMBL13524739 SCHEMBL13524739 0.89 1/20
SCHEMBL13529590 SCHEMBL13529590 0.88 1/20
SCHEMBL317630 SCHEMBL317630 0.86 1/20
SCHEMBL13330482 SCHEMBL13330482 0.86 1/20
SCHEMBL16793994 SCHEMBL16793994 0.86 1/20
SCHEMBL13330479 SCHEMBL13330479 0.85 1/20
SCHEMBL13330509 SCHEMBL13330509 0.85 1/20
SCHEMBL16794292 SCHEMBL16794292 0.84 1/20
SCHEMBL12694513 SCHEMBL12694513 0.83 1/20
SCHEMBL16794367 SCHEMBL16794367 0.83 1/20
SCHEMBL13168045 SCHEMBL13168045 0.82 1/20

Clinical trials — most relevant to CDKL2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Avelumab, Palbociclib and Axitinib in Advanced RCC PHASE2WITHDRAWN
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors PHASE1/PHASE2COMPLETED
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Palbociclib With Everolimus + Exemestane In BC PHASE1/PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy PHASE2COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies PHASE1RECRUITING
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers PHASE1COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
The SONImage Study nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDKL2 binder may also engage these)

ProteinNameSimilarity
Q5R754 — 1.000 Q5R754 →
Q4R7T5 — 1.000 Q4R7T5 →
Q5XIT0 — 0.999 Q5XIT0 →
Q9TTK0 — 0.998 Q9TTK0 →
P50873 — 0.995 P50873 →
Q96287 — 0.994 Q96287 →
P51138 — 0.993 P51138 →
Q8VZD5 — 0.993 Q8VZD5 →
Q8BLF2 — 0.992 Q8BLF2 →
Q9QUK0 — 0.991 Q9QUK0 →
O23145 — 0.991 O23145 →
F4I4F2 — 0.991 F4I4F2 →
Q501Q9 — 0.990 Q501Q9 →
DYRK4 Dual specificity tyrosine-phosphorylation-regulated kinase 4 0.990 landscape →
Q9JM01 — 0.990 Q9JM01 →
STK33 Serine/threonine-protein kinase 33 0.990 landscape →
Q5VP69 — 0.990 Q5VP69 →
P83101 — 0.989 P83101 →
Q5SN53 — 0.989 Q5SN53 →
DYRK3 Dual specificity tyrosine-phosphorylation-regulated kinase 3 0.989 landscape →
G5EBT1 — 0.989 G5EBT1 →
Q4R6S5 — 0.989 Q4R6S5 →
Q9W354 — 0.989 Q9W354 →
Q9FVS6 — 0.989 Q9FVS6 →
B4NSS9 — 0.989 B4NSS9 →
Q86AE1 — 0.989 Q86AE1 →
G5EFD2 — 0.989 G5EFD2 →
P43289 — 0.989 P43289 →
C0RW22 — 0.988 C0RW22 →
Q09831 — 0.988 Q09831 →